Biosimilar Market Dynamics: Small Companies Drive Development, Large Corporations Lead Marketing Efforts

In the ever-evolving landscape of pharmaceuticals, the development and marketing of biosimilars have gained significant momentum. Biosimilars, which are highly similar versions of approved biological drugs, offer a cost-effective alternative for patients while maintaining comparable safety and efficacy. Interestingly, the development of these innovative therapies is primarily driven by smaller companies, while the marketing efforts are predominantly carried out by large corporations.

Biosimilars have emerged as a promising solution to address the growing demand for affordable and accessible biologic therapies. While large pharmaceutical companies have traditionally dominated the industry, smaller biotechnology firms are now taking center stage in the development of biosimilars. These agile and specialized companies possess the scientific expertise and capabilities necessary to navigate the complex regulatory landscape and overcome the technical challenges associated with biosimilar development.

At the end of 2019, Mylan announced the release of their trastuzumab biosimilar. Trastuzumab, formerly known as Herceptin and sold by Genentech, is a monoclonal antibody used to treat breast cancer that has the HER2 gene mutation. The biosimilar version created by Mylan in collaboration with the Indian pharmaceutical firm Biocon Biologics goes by the name Ogivri.

Smaller companies are at the forefront of biosimilar development, investing in research and development to create high-quality therapeutic alternatives. Their nimble organizational structure allows for faster decision-making and adaptability, enabling them to efficiently navigate the intricate process of biosimilar development. These companies employ skilled scientists, clinicians, and regulatory experts who meticulously analyze reference biologics, conduct comparative studies, and ensure bioequivalence to bring safe and effective biosimilars to the market.

Data from a retrospective research from India revealed that Razumab, a ranibizumab biosimilar created by Intas Pharmaceuticals, was safe and effective in treating infant patients with retinopathy of prematurity (ROP). The trial is the first to evaluate the clinical effects of using Razumab in this cohort. Razumab makes reference to Accentrix, commonly known as Lucentis (ranibizumab) in India. The biosimilar has been available in India since 2015 and has helped individuals with neovascular age-related macular degeneration and diabetic macular edoema. Its application in ROP, however, has not yet been researched.

While small companies spearhead biosimilar development, they often collaborate with larger pharmaceutical corporations to leverage their extensive marketing and distribution networks. Large companies possess the resources and infrastructure required to navigate complex regulatory environments, secure market access, and promote biosimilars on a global scale. They bring their commercialization expertise, brand recognition, and market reach to ensure widespread availability and adoption of biosimilars.

The collaboration between smaller companies and large corporations in the biosimilar space enables biosimilars to reach a broader patient population and accelerates market penetration, leading to increased cost savings, improved access to treatments, and enhanced competition in the pharmaceutical market. It is instrumental in driving biosimilar development and commercialization, challenges persist. Intellectual property barriers, regulatory complexities, and the need for robust clinical data pose significant hurdles. However, as the demand for biosimilars continues to rise, it is expected that further partnerships and collaborations will emerge, fostering innovation and facilitating the availability of affordable, high-quality biosimilars across a wide range of therapeutic areas.

A multi-year partnership between Sandoz, a division of Swiss pharmaceutical giant Novartis and Just - Evotec Biologics, a division of German biotech Evotec, was announced in May 2023. The deal includes an option for growth and addresses the research and production of numerous biosimilar medications.
Alteogen Inc. of South Korea and Sandoz AG have agreed to an exclusive licence. A subcutaneous version of a Sandoz biosimilar product will be developed and commercialised using ALT-B4, a novel hyaluronidase generated from Alteogen using Hybrozyme Technology, according to the terms of the agreement. The arrangement also gives Sandoz the option to licence the Hybrozyme technology for two more products.

BioIntel360 suggests that the development and marketing of biosimilars represent a dynamic interplay between smaller companies driving innovation and larger corporations providing commercialization expertise. This partnership holds great promise in expanding access to cost-effective biologic therapies, particularly in the context of cancer treatment. By leveraging their respective strengths, smaller and larger entities are collectively shaping the future of biosimilars, ultimately benefiting patients worldwide through increased affordability, improved treatment options, and enhanced healthcare outcomes.